In conclusion, the addition of avelumab to trastuzumab and FOLFOX had clinically meaningful ORR and PFS in previously untreated metastatic HER2-overexpressing gastric and esophageal adenocarcinomas, corroborating other trials showing activity of immune checkpoint inhibitors added to trastuzumab and fluoropyrimidine/platinum chemotherapy regimens. The gene discussed is ERBB2; the disease is esophageal adenocarcinoma.